Anti-TNR9/ CD137/ TNFRSF9 monoclonal antibody

Anti-TNR9/ CD137/ TNFRSF9 antibody for FACS & in-vivo assay

Target products collectionGo to CD137/TNFRSF9 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T93923-Ab-1/ GM-Tg-hg-T93923-Ab-2Anti-Human CD137/TNFRSF9 monoclonal antibodyHuman
GM-Tg-rg-T93923-Ab-1/ GM-Tg-rg-T93923-Ab-2Anti-Rat CD137/TNFRSF9 monoclonal antibodyRat
GM-Tg-mg-T93923-Ab-1/ GM-Tg-mg-T93923-Ab-2Anti-Mouse CD137/TNFRSF9 monoclonal antibodyMouse
GM-Tg-cynog-T93923-Ab-1/ GM-Tg-cynog-T93923-Ab-2Anti-Cynomolgus/ Rhesus macaque CD137/TNFRSF9 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T93923-Ab-1/ GM-Tg-felg-T93923-Ab-2Anti-Feline CD137/TNFRSF9 monoclonal antibodyFeline
GM-Tg-cang-T93923-Ab-1/ GM-Tg-cang-T93923-Ab-2Anti-Canine CD137/TNFRSF9 monoclonal antibodyCanine
GM-Tg-bovg-T93923-Ab-1/ GM-Tg-bovg-T93923-Ab-2Anti-Bovine CD137/TNFRSF9 monoclonal antibodyBovine
GM-Tg-equg-T93923-Ab-1/ GM-Tg-equg-T93923-Ab-2Anti-Equine CD137/TNFRSF9 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T93923-Ab-1/ GM-Tg-hg-T93923-Ab-2; GM-Tg-rg-T93923-Ab-1/ GM-Tg-rg-T93923-Ab-2;
GM-Tg-mg-T93923-Ab-1/ GM-Tg-mg-T93923-Ab-2; GM-Tg-cynog-T93923-Ab-1/ GM-Tg-cynog-T93923-Ab-2;
GM-Tg-felg-T93923-Ab-1/ GM-Tg-felg-T93923-Ab-2; GM-Tg-cang-T93923-Ab-1/ GM-Tg-cang-T93923-Ab-2;
GM-Tg-bovg-T93923-Ab-1/ GM-Tg-bovg-T93923-Ab-2; GM-Tg-equg-T93923-Ab-1/ GM-Tg-equg-T93923-Ab-2
Products NameAnti-CD137/TNFRSF9 monoclonal antibody
Formatmab
Target NameCD137
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody, Cytokine antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-CD137 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    BiosimilarGMP-Bios-INN-780Pre-Made Cinrebafusp Alfa P Alfaiosimilar, Bispecific, Anti-ERBB2/HER2;TNFRSF9 Antibody: Anti-CD340/MLN 19/NEU/NGL/TKR1/VSCN2;ILA/4-1BB/CDw137 therapeutic antibody
    BiosimilarGMP-Bios-ab-606Pre-Made Utomilumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody
    BiosimilarGMP-Bios-ab-701Pre-Made Tecaginlimab biosimilar, Whole mAb, Anti-CD40;TNFRSF9/CD137 Antibody: Anti-p50/Bp50/CDW40/TNFRSF5;ILA/4-1BB/CDw137 therapeutic antibody
    BiosimilarGMP-Bios-INN-836Pre-Made Ensomafusp Alfa  Alfaiosimilar, Bispecific, Anti-Cd19; Tnfrsf9 Antibody: Anti-B4/CVID3;ILA/4-1BB/CDw137 therapeutic antibody
    BiosimilarGMP-Bios-ab-604Pre-Made Urelumab biosimilar, Whole mAb, Anti-TNFRSF9/CD137 Antibody: Anti-ILA/4-1BB/CDw137 therapeutic antibody
    BiosimilarGMP-Bios-ab-007Pre-Made Acasunlimab biosimilar, Bispecific mAb, Anti-B7-H/B7H1/PDCD1L1/PDCD1LG1/PDL1/hPD-L1;ILA/4-1BB/CDw137 Antibod: Anti-CD274/PD-L1;TNFRSF9/CD137 therapeutic antibody
    Target AntigenProducts DevelopingMulti-species TNR9/ CD137/ TNFRSF9 VLP (virus-like particle) (Products Developing)
    CytokineGM-Tg-g-T93923-Ag-1tumor necrosis factor receptor superfamily, member 9 (TNFRSF9) protein
    ORF Viral VectorpGMLP003848human TNFRSF9 Lentivirus plasmid
    ORF Viral VectorvGMLP003848human TNFRSF9 Lentivirus particle


    Target information

    Target IDGM-T93923
    Target NameCD137
    Gene ID3604,21942,500590,708281,608274,101096582,520341,100058657
    Gene Symbol and Synonyms4-1BB,A930040I11Rik,CD137,CDw137,ILA,IMD109,Ly63,TNFRSF9
    Uniprot AccessionQ07011
    Uniprot Entry NameTNR9_HUMAN
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target, INN Index, Cytokine Target
    DiseaseCancer
    Gene EnsemblENSG00000049249
    Target ClassificationCheckpoint-Immuno Oncology, Tumor-associated antigen (TAA)

    The target: CD137, gene name: TNFRSF9, also named as 4-1BB, CD137, CDw137, ILA. The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contributes to the clonal expansion, survival, and development of T cells. It can also induce proliferation in peripheral monocytes, enhance T cell apoptosis induced by TCR/CD3 triggered activation, and regulate CD28 co-stimulation to promote Th1 cell responses. The expression of this receptor is induced by lymphocyte activation. TRAF adaptor proteins have been shown to bind to this receptor and transduce the signals leading to activation of NF-kappaB. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.